Evidence map›Paper›PMID 27982021›Full record

ReviewCancer gene therapy2017

Circulating exosomes and exosomal microRNAs as biomarkers in gastrointestinal cancer.

R Nedaeinia, M Manian, M H Jazayeri, M Ranjbar, R Salehi, M Sharifi, F Mohaghegh, M Goli, S H Jahednia, A Avan and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 218 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Biocompatible exosomes derived fromRegenerative biomaterials · 2025
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Exosomes in Cancer: Diagnostic and Therapeutic Applications.Clinical Medicine Insights. Oncology · 2024
    Review
  20. Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

R NedaeiniaDepartment of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
M ManianImmunology Research Center, Department of Immunology, Iran University of Medical Science, Tehran, Iran.
M H JazayeriImmunology Research Center, Department of Immunology, Iran University of Medical Science, Tehran, Iran.
M RanjbarDeputy of Food and Drug, Department of Food Control Administration, Isfahan University of Medical Sciences, Isfahan, Iran.
R SalehiDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
M SharifiDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID http://orcid.org/0000-0002-1538-9034
F MohagheghDepartment of Radiotherapy, Arak University of Medical Sciences, Arak, Iran.
M GoliDepartment of Food Science and Technology, Isfahan (Khorasgan) Branch, Islamic Azad University, Isfahan, Iran.
S H JahedniaDepartment of Immunology, Shahid Beheshti University of Medical Science, Tehran, Iran.
A AvanMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
M Ghayour-MobarhanMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Isfahan University of Medical Sciences · IRMashhad University of Medical Sciences · IRIran University of Medical Sciences · IRArak University of Medical Sciences · IRIslamic Azad University, Isfahan · IRShahid Beheshti University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most important biological function of exosomes is their possible use as biomarkers in clinical diagnosis. Compared with biomarkers identified in conventional specimens such as serum or urine, exosomal biomarkers provide the highest amount of sensitivity and specificity, which can be attributed to their excellent stability. Exosomes, which harbor different types of proteins, nucleic acids and lipids, are present in almost all bodily fluids. The molecular constituents of exosomes, especially exosomal proteins and microRNAs (miRNAs), are promising as biomarkers in clinical diagnosis. This discovery that exosomes also contain messenger RNAs and miRNAs shows that they could be carriers of genetic information. Although the majority of RNAs found in exosomes are degraded RNA fragments with a length of <200 nucleotides, some full-length RNAs might be present that may affect protein production in the recipient cell. In addition, exosomal miRNAs have been found to be associated with certain diseases. Several studies have pointed out miRNA contents of circulating exosomes that are similar to those of originating cancer cells. In this review, the recent advances in circulating exosomal miRNAs as biomarkers in gastrointestinal cancers are discussed. These studies indicated that miRNAs can be detected in exosomes isolated from body fluids such as saliva, which suggests potential advantages of using exosomal miRNAs as noninvasive novel biomarkers.

Indexed as

AnimalsBiomarkersExosomesGastrointestinal NeoplasmsGene ExpressionHumansMicroRNAsBiomarkersMicroRNAs

Identifiers

PMID27982021
OpenAlexW2564450069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.